Loading
A blood test at six weeks can show whether a treatment is doing anything. Trials should use it to drop failing combinations fast and move patients on.
Molecular response (ctDNA clearance or fall below a threshold at 6 to 9 weeks) correlates with progression-free and overall survival across several tumour types and drug classes. Platform trials could use pre-specified ctDNA futility rules at 20 patients per arm to stop non-performing combinations months earlier than radiological endpoints allow.
Shares RECIST, Progression-free survival (PFS), Circulating tumour DNA (ctDNA), Trial design, endpoints and cost.
Shares CD8 PET to stop or switch immunotherapy early, RECIST, Progression-free survival (PFS), Circulating tumour DNA (ctDNA).
Shares Natera, Guardant Health, Circulating tumour DNA (ctDNA), Trial design, endpoints and cost.
Shares Natera, Guardant Health, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Natera, Guardant Health, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Guardant Health, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares RECIST, Progression-free survival (PFS), Trial design, endpoints and cost.
Shares RECIST, Progression-free survival (PFS), Trial design, endpoints and cost.